Dimensional Fund Advisors LP Buys 849,721 Shares of Achillion Pharmaceuticals, Inc. (ACHN)

Share on StockTwits

Dimensional Fund Advisors LP boosted its stake in shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) by 14.1% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 6,892,184 shares of the biopharmaceutical company’s stock after buying an additional 849,721 shares during the quarter. Dimensional Fund Advisors LP owned approximately 4.98% of Achillion Pharmaceuticals worth $19,505,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. California State Teachers Retirement System lifted its holdings in Achillion Pharmaceuticals by 11.9% during the 1st quarter. California State Teachers Retirement System now owns 206,482 shares of the biopharmaceutical company’s stock worth $766,000 after buying an additional 22,017 shares during the period. New York State Common Retirement Fund lifted its holdings in Achillion Pharmaceuticals by 24.1% during the 1st quarter. New York State Common Retirement Fund now owns 146,800 shares of the biopharmaceutical company’s stock worth $545,000 after buying an additional 28,500 shares during the period. Element Capital Management LLC acquired a new position in Achillion Pharmaceuticals during the 1st quarter worth about $163,000. Acadian Asset Management LLC acquired a new position in Achillion Pharmaceuticals during the 2nd quarter worth about $135,000. Finally, A.R.T. Advisors LLC lifted its holdings in Achillion Pharmaceuticals by 39.7% during the 1st quarter. A.R.T. Advisors LLC now owns 185,913 shares of the biopharmaceutical company’s stock worth $689,000 after buying an additional 52,800 shares during the period. 78.36% of the stock is currently owned by hedge funds and other institutional investors.

ACHN has been the topic of a number of recent analyst reports. BidaskClub downgraded Achillion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday. Zacks Investment Research raised Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, June 28th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and one has given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $4.38.

Shares of NASDAQ:ACHN opened at $3.13 on Friday. The stock has a market capitalization of $510.00 million, a PE ratio of -5.02 and a beta of 1.27. Achillion Pharmaceuticals, Inc. has a 1 year low of $2.33 and a 1 year high of $4.63.

Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.01. Sell-side analysts predict that Achillion Pharmaceuticals, Inc. will post -0.52 earnings per share for the current fiscal year.

Achillion Pharmaceuticals Profile

Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.

Further Reading: Understanding Compound Annual Growth Rate (CAGR)

Want to see what other hedge funds are holding ACHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).

Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply